Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biopharmaceutical Trends In 2012: Regulatory And Market Strides Paper Over Existential Dilemmas

Jan 25 2013

Related Content

Europe’s Pharma Industry Expects Little Relief In 2013 After Bruising 2012

Jan 14 2013

FDA’s First Breakthrough Designations Continue Vertex <em>Kalydeco</em>’s Regulatory Successes

Jan 07 2013

Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High

Jan 07 2013

FDA Uses AdComm Process To Shine Light On <em>Ampligen</em>’s Troubled Development

Jan 07 2013

FDA’s Very Big Year: Drug Approvals Approach Record Levels

Jan 16 2013

Biopharma IPOs Start To Gear Up For 2013 After A Lull

Jan 21 2013

Will The New Math Of Oncology Drug Review Times Carry Over Into PDUFA V?

Nov 01 2012

Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B

Apr 23 2012

Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling

Dec 10 2012

Lilly And Canadian VCs To Fund TVM Life Sciences VII To Develop Single-Asset Companies

May 29 2012

FDA Wants To Help You Develop Drugs

Dec 06 2012

Off-label Ruling’s Potential Fallout Is “Terrifying,” FDA’s Temple Says

Dec 17 2012

Where Are The Biosimilars?

Dec 14 2012

With <em>Perjeta</em>, The Cost Of HER2 Breast Cancer Therapy Goes Up

Jun 18 2012

Biopharma In 2011: A Year Of Transition

Jan 24 2012

The Orphan Drug Boom: Gold Rush Or Flash In The Pan?

Nov 26 2012

A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy

Nov 26 2012

Too Big To Succeed: Where Are Large Pharmas Heading?

Dec 19 2012

Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin

Jul 30 2012

Solution Development: A Model For Structuring Biotechs And Developing Better Drugs

Sep 12 2012

Merck, GSK, J&J Broaden Strategic LP Relationships, External Discovery Initiatives

Apr 23 2012

J&J’s New Innovation Centers Test Immersion Theory Of Access

Oct 22 2012

IND Over POC: The New Sweet Spot For Biopharma Dealmaking

Oct 01 2011

Related Companies

Vertex Pharmaceuticals Incorporated

AIM Immunotech Inc.

Novartis AG

Pfizer Inc.

Bristol Myers Squibb Company

Protalix BioTherapeutics, Inc.

Nestle Health Science

Abbott

Merck & Co., Inc.

Eli Lilly and Company

Johnson & Johnson

Elan Corporation

Roche Holding AG

Massachusetts Institute of Technology

GSK plc

Johnson & Johnson

Sanofi

Roche Holding AG

Novartis AG

University of Pennsylvania

Bayer AG

Novo Nordisk A/S

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc.

AstraZeneca PLC

Novo Nordisk A/S

Amgen, Inc.

Additional Topics

Strategy Business Strategies Deals BioPharmaceutical

More from Business Strategy

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window